Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway
Open Access
- 1 December 2025
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (2) , 264-275
Abstract
Background: Patients with cancer who had sepsis experience a higher mortality risk than noncancer patients. However, it remains unclear how this risk varies with cancer type and metastasis status, sex, age, and infecting microbe. Methods: This nationwide cohort study included all noncancer patients and those with cancer ≥18 years hospitalized with sepsis in Norway from 2008 to 2021. Cancer status, sepsis, and hospital mortality were identified from the Norwegian Patient Registry (International Classification of Diseases 10th revision codes). Multivariable regression analyses estimated absolute and relative risks (RR) of hospital mortality across subgroups. Results: Of 222,832 hospitalized patients with sepsis, 37,692 (16.9%) had cancer. Hospital mortality was higher in patients with cancer, at 16.9% (males) and 16.2% (females) with nonmetastatic disease, and at 27.1% (males) and 26.2% (females) with metastatic disease. Compared with noncancer patients, adjusted RRs (95% confidence interval) of hospital death were 1.39 (1.34–1.44, males) and 1.63 (1.55–1.71, females) for nonmetastatic cancer and 2.27 (2.18–2.37, males) and 2.75 (2.62–2.89, females) for metastatic cancer. The type of cancer was a key prognostic factor. The association between cancer and mortality was strongest in metastatic patients below 50 years [males 40–49 years: RR, 5.94 (4.43–7.97); females 18–39 years: RR, 8.28 (5.12–13.37)] and in those with gram-negative sepsis. Conclusions: The increased hospital mortality in patients with cancer varied with cancer type and the presence of metastasis. The association between cancer and mortality was strongest in females and young adults, as well as in gram-negative sepsis. Impact: Knowledge of the specific aspects of sepsis in patients with cancer may improve cancer care and guide future research on targeted sepsis therapies.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter AnalysisCancer Medicine, 2024
- Understanding the biases to sepsis surveillance and quality assurance caused by inaccurate coding in administrative health dataInfection, 2023
- Trends in mortality after a sepsis hospitalization: a nationwide prospective registry study from 2008 to 2021Infection, 2023
- Immunopathophysiology of human sepsisEBioMedicine, 2022
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumabIntensive Care Medicine, 2019
- Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)Annals of Hematology, 2019
- Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014JAMA, 2017
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcomaCancer, 2016